Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Long-term Extension Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of TLL-018 in Patients With Rheumatoid Arthritis

NCT06887127 is registered in ClinicalTrials.gov with Hangzhou Highlightll Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT06887127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06887127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Long-term Extension Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of TLL-018 in Patients With Rheumatoid Arthritis
Lead sponsor
Hangzhou Highlightll Pharmaceutical Co., Ltd
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 10, 2025
Completion date
December 31, 2027
Enrollment
350 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis